Breaking News Instant updates and real-time market news.

GE

General Electric

$23.05

-0.02 (-0.09%)

, M

Macy's

$20.24

-0.23 (-1.12%)

07:30
10/13/17
10/13
07:30
10/13/17
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Thursday in General Electric (GE), Macy's (M), Gap (GPS), Juniper (JNPR), AMC Entertainment (AMC), Sprouts Farmers Markets (SFM), HCA Holdings (HCA), and Corcept Therapeutics (CORT).

GE

General Electric

$23.05

-0.02 (-0.09%)

M

Macy's

$20.24

-0.23 (-1.12%)

GPS

Gap

$27.21

-1.21 (-4.26%)

JNPR

Juniper

$25.47

-1.39 (-5.18%)

AMC

AMC Entertainment

$13.85

0.1 (0.73%)

SFM

Sprouts Farmers Market

$18.63

0.36 (1.97%)

HCA

HCA Healthcare

$74.22

-1.31 (-1.73%)

CORT

Corcept Therapeutics

$18.68

-1.385 (-6.90%)

  • 18

    Oct

  • 19

    Oct

  • 20

    Oct

  • 24

    Oct

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 16

    Nov

GE General Electric
$23.05

-0.02 (-0.09%)

10/05/17
MSCO
10/05/17
NO CHANGE
Target $25
MSCO
Equal Weight
General Electric likely to cut FY17 EPS view below $1.50, says Morgan Stanley
Morgan Stanley analyst Nigel Coe said he expects General Electric to lower its FY17 EPS guidance to below $1.50 per share from its currently stated view of $1.60-$1.70 when the company reports earnings on October 20. The analyst, who has $1.40 EPS forecast for the full year, also expects GE to reduce its $12B-$14B CFOA target to closer to $11B and sees scope for the buyback program to be scaled back. Coe, who is not certain if all of this is priced into the stock, is "tactically cautious" into the report and keeps an Equal Weight rating and $25 target price on GE shares.
10/09/17
SBSH
10/09/17
NO CHANGE
Target $31
SBSH
Buy
Citi 'glass half-full' on General Electric management changes
Citi analyst Andrew Kaplowitz says he's taking a "glass half-full" view on General Electric's leadership changes. The analyst is surprised at the "relatively quick" departure of Vice Chair and CFO Jeffrey Bornstein, but believes CEO John Flannery and GE as a whole are effecting a "clean break" from the past. While bears may view the announcement as another signal that GE's recovery could be slower than expected, the changes "likely represent a necessary step toward a more accountable, streamlined, GE," Kaplowitz tells investors in a research note. He keeps a Buy rating on the shares with a $31 price target.
10/09/17
JPMS
10/09/17
NO CHANGE
JPMS
Underweight
GE changes suggest fundamentals worse than expected, says JPMorgan
JPMorgan analyst C. Stephen Tusa believes the management changes announced Friday night by General Electric reinforce his view that the company's core fundamental challenges are "worse than consensus is currently discounting." The analyst keeps an Underweight rating on the shares.
10/11/17
JPMS
10/11/17
NO CHANGE
Target $20
JPMS
Underweight
JPMorgan says GE dividend cut 'increasingly likely,' drops target to $20
JPMorgan analyst C. Stephen Tusa believes a dividend cut at General Electric is "increasingly likely" after the analyst again reduced his estimates. Tusa lowered his estimates to reflect reduced revenues and profits in the Power and Oil & Gas segment as well as higher restructuring expenses. The analyst cut his price target for GE shares to $20 from $22 and keeps an Underweight rating on the name. The stock closed yesterday down 6c to $23.36. With recently added Board members potentially pushing for a quick fix, with all outcomes on the table, a more comprehensive breakup is possible, Tusa tells investors in a research note titled "'Terminal Value': Cutting Numbers, Price Target, and Value of Power in Sum of the Parts." His non-GAAP earnings per share estimates now sit at $1.40/$1.25/$1.40/$1.50 for 2017/2018/2019/2020.
M Macy's
$20.24

-0.23 (-1.12%)

08/11/17
UBSW
08/11/17
NO CHANGE
Target $21
UBSW
Neutral
Macy's Q2 better than feared, guidance hurts confidence, says UBS
UBS analyst Michael Binetti said Macy's reported Q2 results that were better than feared, but its second half guidance has damaged the confidence that its positive trends are sustainable. The analyst lowered his estimates and his price target to $21 from $23. Binetti maintained his Neutral rating on Macy's shares.
09/06/17
COWN
09/06/17
NO CHANGE
Target $23
COWN
Market Perform
Macy's in early innings of leadership transformation, says Cowen
Cowen analyst Oliver Chen believes Macy's is in the early innings of a leadership transformation which he believes should drive increased speed, digital innovation/integration, and accelerated product differentiation. He also sees less negative comps in the second half of 2017 on a continuation of product initiatives and new marketing initiatives. Chen maintained his Market Perform rating and $23 price target on Macy''s shares.
10/04/17
EVER
10/04/17
NO CHANGE
EVER
Macy's added to Model Portfolio as a Short Position at Evercore ISI
06/21/17
GDHS
06/21/17
NO CHANGE
GDHS
Nike-Amazon pact yet another department store headwind, says Gordon Haskett
Gordon Haskett analyst noted the reports of Nike (NKE) nearing a deal to sell directly on Amazon (AMZN), which he said wouldn't impact trends overnight but would represent another headwind for department stores, particularly J.C. Penney (JCP) and Kohl's (KSS), where the brand has a larger penetration than at Macy's (M) and Nordstrom (JWN). He keeps an Accumulate rating on Nordstrom, a Hold rating on Macy's and Reduce rating on both J.C. Penney and Kohl's.
GPS Gap
$27.21

-1.21 (-4.26%)

10/03/17
OPCO
10/03/17
NO CHANGE
Target $33
OPCO
Outperform
Gap price target raised to $33 from $28 at Oppenheimer
Oppenheimer analyst Anna Andreeva raised her price target for Gap to $33 from $28 saying that as big focus on speed and SKU rationalization is leading to greater trend-right full-price selling, management is layering in further cost-savings initiatives, with additional $500M in savings through 2020 more structural in nature. While still a lot of unknowns, the analyst thinks estimates are beatable, and valuation still inexpensive. Andreeva reiterates an Outperform rating on the shares.
09/19/17
LEHM
09/19/17
INITIATION
Target $32
LEHM
Overweight
Gap initiated with an Overweight at Barclays
Barclays analyst Chethan Mallela started Gap with an Overweight rating and $32 price target. The analyst after the close initiated coverage of the U.S. Retail Softlines sector with a Neutral industry view.
09/19/17
09/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Neutral from Underperform at Credit Suisse analyst Christian Buss saying his firm's brick-and-mortar real estate analysis indicates Gap is better positioned than he thought. 2. Michael Kors (KORS) upgraded to Outperform from Perform at Oppenheimer with analyst Anna Andreeva saying the turnaround in retail is just starting, while sentiment on the shares is "extremely negative." 3. McKesson (MCK) upgraded to Outperform from Neutral at Baird with analyst Eric Coldwell calling his rating change a "tactical/trading call" following the shares' material underperformance, both year-to-date and over the last twelve months. 4. NetApp (NTAP) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying NetApp's product position is improved with a re-write of its storage software contributing to all-flash success. 5. Knight-Swift (KNX) resumed with a Buy from Neutral at Citi with analyst Christian Wetherbee saying the truck market recovery appears to be accelerating in the second half of 2017, and Knight-Swift is best levered to an improving truckload market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/17
FBCO
09/19/17
UPGRADE
Target $30
FBCO
Neutral
Gap upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Christian Buss upgraded Gap to Neutral and raised his price target for the shares to $30 from $23. The analyst says his firm's brick-and-mortar real estate analysis indicates Gap is better positioned than he thought. The retailer scored 57.1% versus the group average of 50%, by scoring higher in the mall exposure and mall quality categories, Buss tells investors in a research note. He views Gap's real estate positioning as attractive.
JNPR Juniper
$25.47

-1.39 (-5.18%)

10/12/17
MKMP
10/12/17
NO CHANGE
Target $29
MKMP
Neutral
Juniper price target lowered to $29 from $31 at MKM Partners
MKM Partners analyst Michael Genovese lowered his price target on Juniper Networks (JNPR) to $29 and kept his Neutral rating on the shares, saying that yesterday's Q3 cloud revenue miss reflects completion of large projects and also demonstrates heightened competition from companies like Arista (ANET), which he expects to beat its earnings consensus. Genovese also notes other challenges for Juniper, such as virtualization of routers and reliance on expensive proprietary silicon.
10/11/17
BOFA
10/11/17
DOWNGRADE
Target $31
BOFA
Neutral
Juniper downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Tal Liani downgraded Juniper to Neutral and cut its price target to $31 from $35. The analyst maintains a positive bias on shares but sees more balanced risk/reward given a mix of tough comps, potential weaker carrier capex environment, and limited margin upside. Liani sees no clear positive catalysts for significant outperformance but notes a cash repatriation holiday would be a positive event.
10/12/17
BMOC
10/12/17
NO CHANGE
Target $31
BMOC
Outperform
Juniper Q3 revenue miss not a sign of less traction in cloud, says BMO Capital
BMO Capital analyst Tim Long lowered his price target on Juniper Networks to $31 from $34 following yesterday's weaker than expected Q3 pre-announcement. Long attributes the miss to declining revenue in the cloud vertical after a 29% growth in that space during the first half. However, the analyst contends that the cloud business has "inherent lumpiness" and the Q3 announcement is not indicative of the company's diminishing traction, maintaining an Outperform rating on the stock.
10/12/17
NOMU
10/12/17
DOWNGRADE
Target $27
NOMU
Neutral
Juniper downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal downgraded Juniper Networks to Neutral saying the company preannounced a "sizeable" Q3 miss. While the primary driver was weakness in the cloud vertical, Juniper's routing business may also be weakening, Kvaal tells investors in a research note. He cut his price target for the shares to $27 from $33.
AMC AMC Entertainment
$13.85

0.1 (0.73%)

08/06/17
PIPR
08/06/17
NO CHANGE
Target $25
PIPR
Overweight
AMC Entertainment target lowered to $25 from $35 at Piper Jaffray
Piper Jaffray analyst Stan Meyers lowered his price target for AMC Entertainment to $25 citing the company's "dismal" Q2 results last week. The analyst, however, keeps an Overweight rating on the name. Management's capital allocation initiatives to improve margins "begin to kick in toward the end of the year, just in time for a box office rebound," Meyers tells investors in a Sunday night research note. Even with an 8% rally on Friday to $16.25, shares of the movie theater operator closed last week down 21%.
08/07/17
MKMP
08/07/17
NO CHANGE
MKMP
AMC Entertainment 'big picture' outlook still positive, says MKM Partners
After AMC issued a disappointing preannouncement, MKM Partners analyst Eric Handler blames the miss on Carmike weakness. However, the analyst says that AMC should be boosted over the longer term by "newly instituted cost cuts, ongoing renovation efforts and non-strategic asset sales." He keeps a $28 price target and Buy rating.
09/11/17
SBSH
09/11/17
NO CHANGE
Target $21
SBSH
Buy
AMC Entertainment risk/reward attractive after selloff, says Citi
Citi analyst Jason Bazinet attributes to the decline in 2017 of AMC Entertainment shares to $13 from $31 to fears over windowing, uncertainty about Wanda financing, concerns over leverage as well as the a weaker box office. The analyst sees an attractive risk/reward at current share levels, noting his base case suggests the stock is worth $21. His bull case suggests the equity could reach $32. Bazinet cut his price target for AMC shares to $21 from $30 and keeps a Buy rating on the name.
09/15/17
LOOP
09/15/17
NO CHANGE
LOOP
AMC Entertainment has multiple positive catalysts, says Loop Capital
After meeting with AMC's management, Loop Capital analyst David Miller reports that AMC "has largely fixed" the problems that caused theaters formerly owned by Carmike to underperform in 1H17. Miller quotes AMC's CEO as saying that "the non-renovated Carmike theaters are performing in line with the non-renovated AMC theaters." Miller remains skeptical as to whether premium video on demand will ever launch, and he says that AMC should benefit from easy comps in 2H17 as well as a strong movie slate for the "next five quarters." He says that the stock represents an "exceptional opportunity" for deep value investors. He keeps a $33 price target and a Buy rating on the shares.
SFM Sprouts Farmers Market
$18.63

0.36 (1.97%)

09/15/17
RHCO
09/15/17
NO CHANGE
RHCO
Sprouts Farmers weakness creates buying opportunity, says SunTrust
SunTrust analyst David Magee says that the decline in Sprouts' stock has created a buying opportunity due to its "share gains and advantageous positioning," along with an "improving pricing climate for produce." The analyst cut his price target on the stock to $27 from $29 but keeps a Buy rating on the shares.
08/29/17
WBLR
08/29/17
NO CHANGE
WBLR
Outperform
Sprouts prices still competitive after Whole Foods' cuts, says William Blair
After surveying nearly 100 comparable items in Denver, William Blair analyst Ryan Domyancic found that Sprouts Farmers Market's (SFM) prices remain competitive with Whole Foods Market after Amazon's (AMZN) initial price cuts. For produce, which is Sprouts' leading traffic driver, its average prices on overlapping conventional items were 29% lower on Friday and 23% lower on Monday, Domyancic tells investors in a research note titled "Survey Finds Sprouts Produce Continues to Be Priced at a Significant Discount to Whole Foods." The analyst points out that Sprouts shares have fallen 18% since Amazon announced it would lower prices on Thursday afternoon and are now trading at 10 times his 2017 EBITDA estimate. He finds Sprouts' risk/reward attractive and reiterates an Outperform rating on the name.
10/10/17
RHCO
10/10/17
NO CHANGE
Target $27
RHCO
Buy
Sprouts Farmers not threatened by price cuts at Whole Foods, say SunTrust
SunTrust analyst David Magee maintains his Buy rating and $27 price target on shares of Sprouts Farmers Market, saying the company maintains a "healthy lead" on Whole Foods in conventional produce and is not threatened by its post-Amazon acquisition discounting. Magee adds that most Sprouts Farmers stores are located some distance from those of Whole Foods to reflect differing customer bases of the two brands, though the stock remains constrained in the near term by "less than robust" inflation trends and a rollout of the private Lidl discount grocery chain.
08/29/17
RBCM
08/29/17
NO CHANGE
RBCM
Sprouts prices still significantly lower than Whole Foods, says RBC Capital
RBC Capital analyst William Kirk says that, following price cuts at Amazon's (AMZN) Whole Foods, the overall prices at Sprouts (SFM) "are on average 6.6% lower" than Whole Foods' prices. The analyst reports that fresh produce prices are about 13% lower at Spouts.
HCA HCA Healthcare
$74.22

-1.31 (-1.73%)

09/06/17
CANT
09/06/17
NO CHANGE
CANT
Overweight
Irma threat a risk for HCA, public hospital peers, says Cantor
Cantor Fitzgerald analyst Joseph France noted that HCA Holdings (HCA), Community Health (CYH), LifePoint (LPNT), Tenet (THC) and Envision Healthcare (EVHC) all have business in Florida and Texas and are all down today on the potential threat from Hurricane Irma and the impact from Hurricane Harvey last week. HCA reports nearly half of its beds are in Florida and Texas while Envision has said in the past that more than half of its anesthesia business and about half of its legacy ER business is in those two states, noted France, who adds that Community Health, LifePoint and Tenet are less exposed to those states. The analyst keeps an Overweight rating on HCA shares.
10/13/17
JEFF
10/13/17
NO CHANGE
Target $92
JEFF
Buy
HCA Healthcare price target lowered to $92 from $100 at Jefferies
Jefferies analyst Brian Tanquilut lowered his price target for HCA Healthcare to $92 after revising his estimates to account for several moving parts, including a retroactive reduction in Texas Medicaid Waiver funding and an "uncertain outlook" for healthcare utilization. His analysis, however, suggests HCA's 2018 EBITDA guidance should bracket consensus. Tanquilut calls hurricanes a Q3 "wildcard," believing weather reduced EBITDA in the quarter by greater than $100M. The analyst keeps a Buy rating on HCA shares.
09/14/17
RBCM
09/14/17
NO CHANGE
RBCM
Tenet unlikely to be acquired, says RBC Capital
After The Wall Street Journal reported that Tenet (THC) hired advisors to purse strategic options, RBC Capital analyst Frank Morgan says that all of Tenet probably won't be acquired, given its "significant" debt levels. He says that the company's ambulatory unit is the most likely part of the company to be sold or spun off. The analyst says that HCA (HCA) could be "interested" in some of Tenet's markets, but he does not believe that it wants to buy all of Tenet's hospitals. The analyst does not expect any deals made by Tenet to cause its share price to increase unless it manages to sell its hospitals for rates above their current market value. Morgan keeps a Sector Perform rating on the stock.
09/14/17
DBAB
09/14/17
NO CHANGE
Target $24
DBAB
Buy
Deutsche sees wide range of potential takeout values for Tenet
Deutsche Bank analyst Chris Rigg believes Tenet Healthcare's (THC) leverage makes for an "extremely wide" range of potential buyout prices. After the Wall Street Journal reported that the company is exploring strategic options including a possible sale, Rigg pegs $21-$41 per share as the potential buyout range. Also difficult is determining who would actually be interested and capable of buying Tenet, Rigg tells investors in a research note. HCA Holdings (HCA) has the financial wherewithal to do a deal, but the companies have significant overlap which could bring antitrust issues, the analyst contends. He sees private equity or an existing private equity-backed hospital chain as making more sense. Rigg has a Buy rating on Tenet with a $24 price target.
CORT Corcept Therapeutics
$18.68

-1.385 (-6.90%)

10/11/17
PIPR
10/11/17
NO CHANGE
Target $24
PIPR
Overweight
Piper defends Corcept Therapeutics on yesterday's selloff
Piper Jaffray analyst Charles Duncan attributes the pullback yesterday in shares of Corcept Therapeutics to a "circulating short thesis" centered on Korlym scripts reported by services such as IMS and Symphony Health following the company's switch of specialty pharma distributors in August. The analyst defends the shares as a top second half of 2017 commercial-stage pick following the pullback. Diligence with Korlym prescribers suggests Corcept's education and targeting efforts, as well as larger trends in the treatment of hypercortisolism, can effectively drive Korlym growth in the second half of the year, Duncan tells investors in a research note. Further, he believes the company's specialty pharma distributor switchover went smoothly and is unlikely to adversely impact scripts in the near-term, despite inconsistencies in reporting by services such as IMS. The analyst reiterates an Overweight rating on Corcept with a $24 price target.
10/10/17
STFL
10/10/17
NO CHANGE
STFL
Buy
Corcept selloff due to 'misunderstanding' on Korlym script data, says Stifel
Stifel analyst Adam Walsh attributes today's weakness in shares of Corcept Therapeutics to a "misunderstanding" regarding what appears to be weak data on Korlym scripts. As previously disclosed by the company, Corcept changed its specialty pharmacy distributor for Korlym from Dohmen Life Science to Optime Care. Because of the distributor change it appeared that prescriptions for Korlym had fallen off significantly, noted Walsh, who said he spoke with management and they reiterated their previous statements about Korlym acceleration. The analyst said the weakness is overdone and he keeps a Buy rating on Corcept shares.
09/08/17
PIPR
09/08/17
NO CHANGE
Target $24
PIPR
Overweight
Corcept Therapeutics price target raised to $24 from $18 at Piper Jaffray
08/31/17
08/31/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Neutral at Wedbush. 2. Momo (MOMO) initiated with a Buy at Goldman Sachs. 3. Safety, Income and Growth (SAFE) initiated with a Neutral at Mizuho. 4. Air Industries (AIRI) initiated with a Buy at Roth Capital. 5. Corcept Therapeutics (CORT) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.